About: The forkhead box M1 transcription factor as a candidate of target for anti‐cancer immunotherapy

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The forkhead box M1 transcription factor as a candidate of target for anti‐cancer immunotherapy Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	The forkhead box M1 transcription factor as a candidate of target for anti‐cancer immunotherapy
Creator	Baba, Hideo Daigo, Yataro Harao, Michiko Hayashida, Yuki Ikuta, Yoshiaki »more»
source	Medline; PMC
abstract	The present study attempted to identify a target antigen for immunotherapy for cholangiocarcinoma. Forkhead box M1 (FOXM1) was selected as a candidate antigen based on the data of previous cDNA microarray analysis of clinical samples of cholangiocarcinoma. The level of FOXM1 mRNA was more than 4 times higher in cancer cells in comparison to adjacent normal epithelial cells, in all of 24 samples of cholangiocarcinoma tissues. An immunohistochemical analysis also detected FOXM1 protein in the cancer cells but not in the normal cells. Twenty‐three human FOXM1‐derived peptides predicted to bind to HLA‐A2 were analyzed to determine their ability to induce HLA‐A2‐restricted T cells in HLA‐A2 transgenic mice. FOXM1(362‐370) (YLVPIQFPV), FOXM1(373‐382) (SLVLQPSVKV), and FOXM1(640‐649) (GLMDLSTTPL) peptides primed HLA‐A2‐restricted cytotoxic T lymphocytes (CTLs) in the HLA‐A2 transgenic mice. Human CTL lines reactive to these 3 peptides could also be established from HLA‐A2‐positive healthy donors and cancer patients. Natural processing of the 3 epitopes from FOXM1 protein was confirmed by specific killing of HLA‐A2‐positive FOXM1‐transfectants by peptide‐induced CTLs. FOXM1 is expressed in various types of cancers and it is also functionally involved in oncogenic transformation and the survival of cancer cells. Therefore, FOXM1 may be a suitable target for immunotherapy against various cancers including cholangiocarcinoma.
has issue date	2009-08-17(xsd:dateTime)
bibo:doi	10.1002/ijc.24836
bibo:pmid	19688828
has license	no-cc
sha1sum (hex)	d17ebd82fed5539471e8e0f8d2c496efa14851a9
schema:url	https://doi.org/10.1002/ijc.24836
resource representing a document's title	The forkhead box M1 transcription factor as a candidate of target for anti‐cancer immunotherapy
has PubMed Central identifier	PMC7165995
has PubMed identifier	19688828
schema:publication	Int J Cancer
resource representing a document's body	covid:d17ebd82fed5539471e8e0f8d2c496efa14851a9#body_text
is schema:about of	named entity 'determine' named entity 'ability' named entity '4 TIMES' named entity 'EPITHELIAL CELLS' named entity 'FOXM1' »more»

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software